Edoxaban (DU-176b, trade names Savaysa, Lixiana) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.
Medical uses
US FDA-labeled indications:
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.
To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF)
Product:
Product：Edoxaban
CAS No. 480449-70-5
Molecular Formula: C24H30ClN7O4S
Molecular Weight: 548.065
Appearance: White powder
Specification: 98%
Specifications:
the quality of our Edoxaban base
| Item | Requirements | Test Results |
| Appearance | white crystalline powder | Complies |
| Melting point | 180.0℃~188.0℃ | 182.5℃~184.8℃ |
| Loss on drying | ≤0.50% | 0.20% |
| Residue on ignition | ≤0.20% | 0.10% |
| Heavy Metal | ≤20ppm | Complies |
| Each impurity | ≤0.50% | 0.24% |
| T.L.C | Only one spot | Only one spot |
| Assay | ≥98.5% | 99.0% |
| Conclusion | Meets the Requirements | |
Packaging & Shipping:
Packaging Details:
25kgs packaging Fiber drum outside and plastic bag inside 1-25kgs packaging aluminium bag outside and double plastic bag inside
Delivery Detail: within 3 days when get the payment
Shipping :
We have Professional shipping agent, based on customers ' demand for transport
By express :FEDEX,DHL,EMS ,UPS,TNT ect.
By SEA and By AIR
没有评论:
发表评论